Results 111 to 120 of about 399,367 (396)

Mechanical Interactions Impact the Functions of Immune Cells and Their Application in Immunoengineering

Advanced Therapeutics, EarlyView.
This review covers the mechanical forces experienced by immune cells through cell–cell and cell–extracellular matrix interactions and how these forces influence their receptors and functions. These relationships between forces and cellular functions can be exploited using engineering techniques to modify the physical properties of materials for novel ...
Yu‐Chang Chen, Nghi M. Tran, Kyle H. Vining   +2 more
wiley   +1 more source

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]

, 2002
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Bowen, D.T., Frew, M.E., Gale, R.E., Kottaridis, P.D., Langabeer, S.E., Linch, D.C.   +5 more
core   +1 more source

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML

Molecular Therapy: Oncolytics, 2021
Resistance to the BCR-ABL inhibitor imatinib mesylate poses a major problem for the treatment of chronic myeloid leukemia. Imatinib resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding.
Yanjun Liu, Chuting Li, Rui Su, Zhao Yin, Guiping Huang, Juhua Yang, Zhendong Li, Keda Zhang, Jia Fei   +8 more
doaj  

Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation

Haematologica, 2014
Inherited or sporadic heterozygous mutations in the transcription factor GATA2 lead to a clinical syndrome characterized by non-tuberculous mycobacterial and other opportunistic infections, a severe deficiency in monocytes, B cells and natural killer ...
Robert R. West, Amy P. Hsu, Steven M. Holland, Jennifer Cuellar-Rodriguez, Dennis D. Hickstein   +4 more
doaj   +1 more source

The concept of treatment-free remission in chronic myeloid leukemia

Leukemia, 2016
The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is approaching that of the general population but lifelong treatment is still ...
Susanne Saussele, J. Richter, A. Hochhaus, F. Mahon   +3 more
semanticscholar   +1 more source

Microphysiological Systems in Cancer Research: Advancing Immunotherapy through Tumor Microenvironment‐Integrated Organ‐On‐Chip Models

Advanced Therapeutics, EarlyView.
Emerging microphysiological systems reproduce the spatial, biochemical, and cellular complexity of the tumor microenvironment, surpassing 2D cultures and murine models. By integrating patient‐derived tumors, perfusable vasculature, and immune trafficking, these organ‐on‐chip platforms reveal mechanisms of immune evasion, predict therapeutic responses ...
Fabiana Moresi, Francesco Noto, Jyothsna Vasudevan, Xavier Bisteau, Giulia Adriani, Andrea Pavesi   +5 more
wiley   +1 more source

Questions and answers about leukemia [PDF]

Leukemia is cancer of the white blood cells. It develops in the bone marrow and spreads into the blood and to other organs. There are several types of leukemia. They are grouped in two ways: by how rapidly the disease develops (acute vs. chronic leukemia)

core  

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

PATHOMORPHOLOGICAL ANALYSIS OF TREPANOBIOPTATES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOCYTIC LEUKEMIA: ASSESSMENT OF THE PROGNOSTIC VALUE OF MYELOFIBROSIS WHEN COMPARED WITH CLINICAL DATA

Сибирский научный медицинский журнал, 2019
The aim of the study was to study the relationship between the qualitative and quantitative characteristics of myelofibrosis and the clinical manifestations of chronic myeloid leukemia and chronic lymphocytic leukemia. Material and methods.
T. Y. Dolgikh, E. V. Vinogradova, V. I. Kapustina, S. R. Senchukova   +3 more
doaj   +1 more source

Chronic Myeloid Leukemia

DeckerMed Medicine, 2015
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, chronic myelocytic leukemia, and chronic granulocytic leukemia, is characterized by the expansion of myeloid progenitor cells at various stages of maturation, their premature release into the circulation, and a tendency to home to extramedullary sites.
Elias Jabbour, Susan O'Brien
openaire   +1 more source